<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Furosemide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00695</strong>&#160; (APRD00608, DB07799)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00695/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00695/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00695.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00695.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00695.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00695.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00695.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00695">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Frusemide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>Former BAN</td></tr><tr><td>Furosemid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Furosemida</td><td>Spanish</td><td>INN</td></tr><tr><td>Furosemidu</td><td>Polish</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Furosemidum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Diurapid</td><td>Mibe Jena</td></tr><tr><td>Diurin</td><td>Mylan</td></tr><tr><td>Diurmessel</td><td>Biomep</td></tr><tr><td>Eutensin</td><td>Sanofi</td></tr><tr><td>Frumex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Frusenex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Frusol</td><td>Rosemont</td></tr><tr><td>Furo-Puren</td><td>Actavis</td></tr><tr><td>Lasix</td><td>Sanofi</td></tr><tr><td>Seguril</td><td>Sanofi</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/diuretics">Diuretics</a></li>
<li><a href="/mesh/sodium-potassium-chloride-symporter-inhibitors">Sodium Potassium Chloride Symporter Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>54-31-9</td></tr><tr><th>Weight</th><td>Average: 330.744<br>Monoisotopic: 330.007719869</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>11</sub>ClN<sub>2</sub>O<sub>5</sub>S</td></tr><tr><th>InChI Key</th><td>ZZUFCTLCJUWOSV-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Benzenesulfonamides</td></tr><tr><th>Direct parent</th><td>Aminobenzenesulfonamides</td></tr><tr><th>Alternative parents</th><td>Aminobenzoic Acid Derivatives; Benzoic Acids; Benzoyl Derivatives; Chlorobenzenes; Aryl Chlorides; Sulfonyls; Furans; Sulfonamides; Polyamines; Carboxylic Acids; Enolates; Secondary Amines; Organochlorides</td></tr><tr><th>Substituents</th><td>benzoic acid; benzoic acid or derivative; benzoyl; chlorobenzene; aryl halide; aryl chloride; sulfonic acid derivative; sulfonamide; furan; sulfonyl; enolate; polyamine; secondary amine; carboxylic acid; carboxylic acid derivative; amine; organohalogen; organonitrogen compound; organochloride</td></tr><tr><th>Classification description</th><td>This compound belongs to the aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Also for the treatment of hypertension alone or in combination with other antihypertensive agents.</td></tr><tr><th>Pharmacodynamics</th><td>Furosemide, a sulfonamide-type loop diuretic structurally related to bumetanide, is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome.</td></tr><tr><th>Mechanism of action</th><td>Furosemide, a loop diuretic, inhibits water reabsorption in the nephron by blocking the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. This is achieved through competitive inhibition at the chloride binding site on the cotransporter, thus preventing the transport of sodium from the lumen of the loop of Henle into the basolateral interstitium. Consequently, the lumen becomes more hypertonic while the interstitium becomes less hypertonic, which in turn diminishes the osmotic gradient for water reabsorption throughout the nephron. Because the thick ascending limb is responsible for 25% of sodium reabsorption in the nephron, furosemide is a very potent diuretic.</td></tr><tr><th>Absorption</th><td>60% absorbed in patients with normal renal function</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>95% bound to plasma proteins</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Only a small amount is hepatically metabolized to the defurfurylated derivative, 4-chloro-5-sulfamoylanthranilic acid.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Furosemide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00729">4-chloro-5-sulfamoylanthranilic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/750">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Furosemide is excreted in urine. Significantly more furosemide is excreted in urine following the I.V. injection than after the tablet or oral solution.</td></tr><tr><th>Half life</th><td>2 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Profound diuresis may cause fluid and electrolyte depletion. Excessive dehydration and potassium depletion may occur. Excessive diuresis may cause rapid weight loss, orthostatic hypotension or acute hypotensive episodes. May also cause tinnitus, reversible or permanent hearing loss or reversible deafness. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Furosemide Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9155</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.8833</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6436</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.8775</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9272</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8382</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.924</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6878</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8351</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6789</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9602</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6885</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.6469
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9881
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1362 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9342
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8525
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Abraxis pharmaceutical products</li>
<li>App pharmaceuticals llc</li>
<li>Astrazeneca lp</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Hospira inc</li>
<li>International medication system</li>
<li>Luitpold pharmaceuticals inc</li>
<li>Marsam pharmaceuticals llc</li>
<li>Organon usa inc</li>
<li>Smith and nephew solopak div smith and nephew</li>
<li>Warner chilcott div warner lambert co</li>
<li>Watson laboratories inc</li>
<li>Wockhardt ltd</li>
<li>Wyeth ayerst laboratories</li>
<li>Sanofi aventis us llc</li>
<li>Roxane laboratories inc</li>
<li>Wockhardt eu operations (swiss) ag</li>
<li>Dava pharmaceuticals inc</li>
<li>Excellium pharmaceutical inc</li>
<li>International medication systems ltd</li>
<li>Ipca laboratories ltd</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Kalapharm inc</li>
<li>Mutual pharmaceutical co inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Sandoz inc</li>
<li>Superpharm corp</li>
<li>Vintage pharmaceuticals inc</li>
<li>County line pharmaceuticals llc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.americanregent.com">American Regent</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li>C.O. Truxton Inc.</li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.chcsct.com">Central Texas Community Health Centers</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>Coupler Enterprises Inc.</li>
<li><a href="http://www.cvs.com">CVS Pharmacy</a></li>
<li><a href="http://www.davapharma.com">DAVA Pharmaceuticals</a></li>
<li>Dept Health Central Pharmacy</li>
<li>DHHS Program Support Center Supply Service Center</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.excellium.com">Excellium Pharmaceutical Inc.</a></li>
<li><a href="http://www.giv.com">General Injectables and Vaccines Inc.</a></li>
<li>Goldline Laboratories Inc.</li>
<li><a href="http://www.ghc.org">Group Health Cooperative</a></li>
<li><a href="http://www.hhlabs.com">H and H Laboratories</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.intervet.ca">Intervet International</a></li>
<li><a href="http://www.ipcalabs.com">Ipca Laboratories Ltd.</a></li>
<li>Ivax Pharmaceuticals</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.luitpold.com">Luitpold Pharmaceuticals Inc.</a></li>
<li>Macnary Ltd.</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li>Mason Distributors</li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.medvantx.com">Medvantx Inc.</a></li>
<li>Merrell Pharmaceuticals Inc.</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neighborcare Repackaging Inc.</li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.norwichpharma.com">Norwich Pharmaceuticals Inc.</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.ohmlabs.com">Ohm Laboratories Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.patheon.com">Patheon Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.sanofi-aventis.com">Sanofi-Aventis Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li>
<li><a href="http://www.stat-scripts.com">Stat Scripts LLC</a></li>
<li>Talbert Medical Management Corp.</li>
<li>Taylor Pharmaceuticals</li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li>
<li>Va Cmop Dallas</li>
<li>Vangard Labs Inc.</li>
<li>Vatring Pharmaceuticals</li>
<li><a href="http://www.vedco.com">Vedco Inc.</a></li>
<li>Vintage Pharmaceuticals Inc.</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intramuscular</td><td></td></tr><tr><td>Solution</td><td>Intravenous</td><td></td></tr><tr><td>Solution</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/1811">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1875">MS/MS Spectrum Quattro_QQQ 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1876">MS/MS Spectrum Quattro_QQQ 25</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1877">MS/MS Spectrum Quattro_QQQ 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1751">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00479">Amikacin</a></td><td>Increased ototoxicity</td></tr><tr><td><a href="/drugs/DB00515">Cisplatin</a></td><td>Increased ototoxicity</td></tr><tr><td><a href="/drugs/DB00930">Colesevelam</a></td><td>Bile acid sequestrants such as colesevelam may decrease the absorption of loop diuretics such as furosemide.  Monitor for decreased serum concentrations/therapeutic effects of loop diuretics if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. </td></tr><tr><td><a href="/drugs/DB01078">Deslanoside</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB01396">Digitoxin</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>Possible electrolyte variations and arrhythmias</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>The hydantoin decreases the effect of furosemide</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The hydantoin decreases the effect of furosemide</td></tr><tr><td><a href="/drugs/DB00798">Gentamicin</a></td><td>Increased ototoxicity</td></tr><tr><td><a href="/drugs/DB01404">Ginseng</a></td><td>Ginseng decreases the therapeutic effect</td></tr><tr><td><a href="/drugs/DB01050">Ibuprofen</a></td><td>The NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, furosemide.</td></tr><tr><td><a href="/drugs/DB05039">Indacaterol</a></td><td>Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. </td></tr><tr><td><a href="/drugs/DB00328">Indomethacin</a></td><td>The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, furosemide.</td></tr><tr><td><a href="/drugs/DB01172">Kanamycin</a></td><td>Increased ototoxicity</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>The hydantoin decreases the effect of furosemide</td></tr><tr><td><a href="/drugs/DB00955">Netilmicin</a></td><td>Increased ototoxicity</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>The hydantoin decreases the effect of furosemide</td></tr><tr><td><a href="/drugs/DB01082">Streptomycin</a></td><td>Increased ototoxicity</td></tr><tr><td><a href="/drugs/DB00605">Sulindac</a></td><td>The NSAID, sulindac, may decrease the diuretic and antihypertensive effects of the loop diuretic, furosemide.</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Increased ototoxicity</td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>The loop diuretic, Furosemide, may increase the hypotensive effect of Trandolapril. Furosemide may also increase the nephrotoxicity of Trandolapril. </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid excess salt/sodium unless otherwise instructed by your physician.</li>
<li>Increase potassium intake; add a banana or orange juice; unless instructed otherwise.</li>
<li>Take with food to reduce irritation.</li></ul></td></tr></tbody></table>